Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity

Biochemical Pharmacology

Volumn 74, Issue 10, 2007, Pages 1437-1444

  Beretta, Giovanni Luca ^a   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antitumor pharmacology; Camptothecin; DNA damage; DNA topoisomerase; Human serum albumin; Transporters

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; ESTERASE; HUMAN SERUM ALBUMIN; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; COVALENT BOND; DNA STRAND BREAKAGE; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; EXTRACELLULAR SPACE; HUMAN; IN VIVO STUDY; INTRACELLULAR SPACE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 35348914686     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.04.027     Document Type: Note

References (73)

1. Fassberg J., and Stella V.J. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81 (1992) 676-684
2. Nabiev I., Fleury F., Kudelina I., Pommier Y., Charton F., Riou J.F., et al. Spectroscopic and biochemical characterisation of self-aggregates formed by antitumor drugs of the camptothecin family: their possible role in the unique mode of drug action. Biochem Pharmacol 55 (1998) 1163-1174
3. Mi Z., and Burke T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33 (1994) 10325-10336
4. Fleury F., Kudelina I., and Nabiev I. Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins. FEBS Lett 406 (1997) 151-156
5. Burke T.G., Munshi C.B., Mi Z., and Jiang Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84 (1995) 518-519
6. Loos W.J., Verweij J., Gelderblom H.J., de Jonge M.J., Brouwer E., Dallaire B.K., et al. Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans. Anticancer Drugs 10 (1999) 705-710
7. Mi Z., Malak H., and Burke T.G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34 (1995) 13722-13728
8. Bom D., Curran D.P., Kruszewski S., Zimmer S.G., Thompson Strode J., Kohlhagen G., et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43 (2000) 3970-3980
9. Bom D., Curran D.P., Zhang J., Zimmer S.G., Bevins R., Kruszewski S., et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 74 (2001) 325-333
10. Burke T.G., and Mi Z. Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36 (1993) 2580-2582
11. Pratesi G., Beretta G.L., Zunino F., and Gimatecan. a novel camptothecin with a promising preclinical profile. Anticancer Drugs 15 (2004) 545-552
12. Sessa C., Cresta S., Cerny T., Baselga J., Caremoli E., Malossi A., et al. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol 18 (2007) 561-568
13. Harel M., Hyatt J.L., Brumshtein B., Morton C.L., Wadkins R.M., Silman I., et al. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase. Chem Biol Interact 157/158 (2005) 153-157
14. Morton C.L., Wadkins R.M., Danks M.K., and Potter P.M. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59 (1999) 1458-1463
15. Danks M.K., Morton C.L., Pawlik C.A., and Potter P.M. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 58 (1998) 20-22
16. Wierdl M., Morton C.L., Weeks J.K., Danks M.K., Harris L.C., and Potter P.M. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 61 (2001) 5078-5082
17. Gandia D., Abigerges D., Armand J.P., Chabot G., Da Costa L., De Forni M., et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 11 (1993) 196-197
18. Abigerges D., Chabot G.G., Armand J.P., Herait P., Gouyette A., and Gandia D. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13 (1995) 210-221
19. Hyatt J.L., Tsurkan L., Morton C.L., Yoon K.J., Harel M., Brumshtein B., et al. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. Chem Biol Interact 157/158 (2005) 247-252
20. Gupta E., Luo F., Lallo A., Ramanathan S., Vyas V., Rubin E., et al. The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s). Anticancer Res 20 (2000) 1013-1016
21. Ma J., Maliepaard M., Nooter K., Loos W.J., Kolker H.J., Verweij J., et al. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 77 (1998) 1645-1652
22. Dean M., and Allikmets R. Evolution of ATP-binding cassette transporter genes. Curr Opin Genet Dev 5 (1995) 779-785
23. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., and Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39 (1999) 361-398
24. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58 (2001) 931-959
25. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71 (2002) 537-592
26. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58
27. Chen A.Y., Yu C., Potmesil M., Wall M.E., Wani M.C., and Liu L.F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51 (1991) 6039-6044
28. Fardel O., Lecureur V., and Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 27 (1996) 1283-1291
29. Sharom F.J. The P-glycoprotein efflux pump: how does it transport drugs?. J Membr Biol 160 (1997) 161-175
30. van Hattum A.H., Pinedo H.M., Schluper H.M., Erkelens C.A., Tohgo A., and Boven E. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem Pharmacol 64 (2002) 1267-1277
31. Koike K., Kawabe T., Tanaka T., Toh S., Uchiumi T., Wada M., et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57 (1997) 5475-5479
32. Leggas M., Adachi M., Scheffer G.L., Sun D., Wielinga P., Du G., et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24 (2004) 7612-7621
33. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
34. Chen Z.S., Furukawa T., Sumizawa T., Ono K., Ueda K., Seto K., et al. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55 (1999) 921-928
35. Loe D.W., Deeley R.G., and Cole S.P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res 58 (1998) 5130-5136
36. Schuetz J.D., Connelly M.C., Sun D., Paibir S.G., Flynn P.M., Srinivas R.V., et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5 (1999) 1048-1051
37. Tian Q., Zhang J., Chan S.Y., Tan T.M., Duan W., Huang M., et al. Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 7 (2006) 105-118
38. Ejendal K.F., and Hrycyna C.A. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 3 (2002) 503-511
39. Ross D.D., Yang W., Abruzzo L.V., Dalton W.S., Schneider E., Lage H., et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91 (1999) 429-433
40. Honjo Y., Hrycyna C.A., Yan Q.W., Medina-Perez W.Y., Robey R.W., van de Laar A., et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61 (2001) 6635-6639
41. Allen J.D., Jackson S.C., and Schinkel A.H. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res 62 (2002) 2294-2299
42. Muller M., Meijer C., Zaman G.J., Borst P., Scheper R.J., Mulder N.H., et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91 (1994) 13033-13037
43. Maliepaard M., van Gastelen M.A., de Jong L.A., Pluim D., van Waardenburg R.C., Ruevekamp-Helmers M.C., et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59 (1999) 4559-4563
44. Allen J.D., Brinkhuis R.F., Wijnholds J., and Schinkel A.H. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59 (1999) 4237-4241
45. Yang C.H., Schneider E., Kuo M.L., Volk E.L., Rocchi E., and Chen Y.C. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 60 (2000) 831-837
46. Mao Q., and Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7 (2005) E118-E133
47. Perego P., De Cesare M., De Isabella P., Carenini N., Beggiolin G., Pezzoni G., et al. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61 (2001) 6034-6037
48. Brangi M., Litman T., Ciotti M., Nishiyama K., Kohlhagen G., Takimoto C., et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59 (1999) 5938-5946
49. Nakagawa H., Saito H., Ikegami Y., Aida-Hyugaji S., Sawada S., and Ishikawa T. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett 234 (2006) 81-89
50. Bates S.E., Medina-Perez W.Y., Kohlhagen G., Antony S., Nadjem T., Robey R.W., et al. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J Pharmacol Exp Ther 10 (2004) 836-842
51. Rajendra R., Gounder M.K., Saleem A., Schellens J.H., Ross D.D., Bates S.E., et al. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 63 (2003) 3228-3233
52. Maliepaard M., van Gastelen M.A., Tohgo A., Hausheer F.H., van Waardenburg R.C., de Jong L.A., et al. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7 (2001) 935-941
53. Croce A.C., Bottiroli G., Supino R., Favini E., Zuco V., and Zunino F. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol 67 (2004) 1035-1045
54. Petrangolini G., Supino R., Pratesi G., Dal Bo L., Tortoreto M., Croce A.C., et al. Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther 318 (2006) 939-946
55. Adams D.J., Wahl M.L., Flowers J.L., Sen B., Colvin M., Dewhirst M.W., et al. Camptothecin analogs with enhanced activity against human breast cancer cells II. Impact of the tumor pH gradient. Cancer Chemother Pharmacol 57 (2006) 145-154
56. Pommier Y., and Cherfils J. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol Sci 26 (2005) 138-145
57. Staker B.L., Hjerrild K., Feese M.D., Behnke C.A., Burgin Jr. A.B., and Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 99 (2002) 15387-15392
58. Staker B.L., Feese M.D., Cushman M., Pommier Y., Zembower D., Stewart L., et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 48 (2005) 2336-2345
59. Dallavalle S., Delsoldato T., Ferrari A., Merlini L., Penco S., Carenini N., et al. Novel 7-substituted camptothecins with potent antitumor activity. J Med Chem 43 (2000) 3963-3969
60. De Cesare M., Pratesi G., Perego P., Carenini N., Tinelli S., Merlini L., et al. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res 61 (2001) 7189-7195
61. Dallavalle S., Ferrari A., Biasotti B., Merlini L., Penco S., Gallo G., et al. Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. J Med Chem 44 (2001) 3264-3274
62. Dallavalle S., Merlini L., Morini G., Musso L., Penco S., Beretta G.L., et al. Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin. Eur J Med Chem 39 (2004) 507-513
63. Pratesi G., De Cesare M., Carenini N., Perego P., Righetti S.C., Cucco C., et al. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts. Clin Cancer Res 8 (2002) 3904-3909
64. Wadkins R.M., Bears D., Manikumar G., Wani M.C., Wall M.E., and Von Hoff D.D. Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Cancer Res 64 (2004) 6679-6683
65. De Cesare M., Beretta G.L., Tinelli S., Benedetti V., Pratesi G., Penco S., et al. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol 73 (2007) 656-664
66. Dallavalle S., Giannini G., Alloatti D., Casati A., Marastoni E., Musso L., et al. Synthesis and cytotoxic activity of polyamine analogues of camptothecin. J Med Chem 49 (2006) 5177-5186
67. Laco G.S., Collins J.R., Luke B.T., Kroth H., Sayer J.M., Jerina D.M., et al. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model. Biochemistry 41 (2002) 1428-1435
68. Hertzberg R.P., Caranfa M.J., Holden K.G., et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 32 (1989) 715-720
69. Thomas C.J., Rahier N.J., and Hecht S.M. Camptothecin: current perspectives. Bioorg Med Chem 12 (2004) 1585-1604
70. Hsiang Y.H., Liu L.F., Wall M.E., et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49 (1989) 4385-4389
71. Beretta G.L., Petrangolini G., De Cesare M., Pratesi G., Perego P., Tinelli S., et al. Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. Cancer Res 66 (2006) 10976-10982
72. Zunino F., and Pratesi G. Camptothecins in clinical development. Expert Opin Investig Drugs 13 (2004) 269-284
73. Duvvuri M., Konkar S., Hong K.H., Blagg B.S., and Krise J.P. A new approach for enhancing differential selectivity of drugs to cancer cells. ACS Chem Biol 1 (2006) 309-315